CHKA and cancer: Mechanistic investigation has elucidated that the molecular causes of aberrant choline metabolism in cancers arise from alterations in enzymes that control the anabolic and catabolic pathways of PC, including choline kinase α (CHKα), PC-specific phospholipase C (PC-PLC), PC-PLD1 and glycerophosphocholine phosphodiesterases (GPCPDs), which are often associated with up-regulated expression and activity of several choline transporters [1,2,4,6].